GLP-1 receptor agonists cut obesity-associated cancer risk by 41% in obese, nondiabetic adults
Background
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce cancer incidence in diabetic and general obese populations, their specific impact on obesity-associated cancer (OAC) risks in obese, nondiabetic patients has been underexplored. Obesity is a significant risk factor for various cancers, and current interventions primarily focus on weight management. This study addresses a critical gap by exclusively investigating the potential chemopreventive role of GLP-1RAs in this high-risk, yet understudied, demographic, seeking to expand the therapeutic utility of these agents beyond metabolic control.
Study Design
Researchers conducted a target trial emulation using TriNetX, a nationwide database of 113 million US patients, to assess the association between GLP-1RA use and the risk of 13 OACs. They identified obese, nondiabetic adults without prior OAC diagnosis from December 2014 to June 2025. Patients prescribed GLP-1RAs were 1:1 propensity score matched to those receiving diet or exercise counseling. The primary outcome compared the cumulative incidence of OACs between groups, with secondary analyses across subgroups including sex, BMI (<40, ≥40 kg/m2), race, and specific drugs like semaglutide and tirzepatide. Findings were validated using inverse probability of treatment weighting.
Results
The initial cohort comprised 229,467 patients, with 86,422 (37.7%) receiving GLP-1RAs and 143,045 (62.3%) receiving diet or exercise counseling. After 1:1 propensity score matching, the study cohort included 161,798 patients (80,899 GLP-1RA users versus 80,899 controls). The mean age was 47.2 years (SD 14.8), with a median follow-up of 2 years (IQR 1-2 years).
Key Findings
- GLP-1RA use associated with 41% lower incidence of obesity-associated cancers (OACs) (HR 0.59, 95% CI 0.53-0.67).
- Study included 161,798 propensity-score matched obese, nondiabetic adults.
- Median follow-up period was 2 years (interquartile range 1-2 years).
- Lower OAC incidence observed across most subgroups, including semaglutide and tirzepatide users.
- The association held true for all subgroups except for black race.
Why It Matters
This study provides compelling evidence that GLP-1RAs may offer a significant chemopreventive benefit against obesity-associated cancers in obese, nondiabetic individuals, extending their utility beyond weight loss and glycemic control. For peptide users and clinicians, this suggests that GLP-1RA therapy could be considered not only for metabolic health but also as a strategy to reduce long-term cancer risk in this specific population. While the median follow-up was 2 years, these short-term findings are highly impactful, potentially influencing prescribing guidelines and encouraging further research into the anti-cancer mechanisms of GLP-1R activation. This expands the rationale for long-term GLP-1RA use in obese individuals without diabetes.
glp-1ra
semaglutide
tirzepatide
obesity
cancer
prevention